100 Participants Needed

Aprepitant for Postoperative Nausea and Vomiting

MK
TD
Overseen ByTristain Dumbarton, MD
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using any medication that severely interacts with Aprepitant.

What data supports the effectiveness of the drug aprepitant for preventing postoperative nausea and vomiting?

Research shows that aprepitant significantly reduces vomiting on the first and second days after surgery compared to other treatments, with fewer patients needing additional medication to control symptoms.12345

Is aprepitant safe for humans?

Aprepitant is generally considered safe for humans, as studies show it effectively prevents nausea and vomiting after surgery without major adverse effects.12567

How is the drug aprepitant unique for treating postoperative nausea and vomiting?

Aprepitant is unique because it works by blocking neurokinin-1 (NK-1) receptors, which is different from many other treatments that target serotonin receptors. It has been shown to provide better protection against vomiting and has a longer-lasting effect, reducing the need for additional medication after surgery.13478

What is the purpose of this trial?

This research trial will measure how useful Aprepitant is in preventing nausea and vomiting in children having surgery to correct scoliosis (curvature of the spine).

Research Team

MK

Mathew Kiberd, MD

Principal Investigator

IWK Health Centre

Eligibility Criteria

This trial is for children aged 8-18 undergoing scoliosis surgery to correct spinal curvature. They must weigh over 40kg and have a spinal fusion involving at least six vertebral levels. It's not suitable for those who don't meet these specific surgical or age requirements.

Inclusion Criteria

I had spinal surgery for scoliosis.
My spine surgery involved fusing 6 or more vertebrae together.
I weigh more than 40kg.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Aprepitant or placebo to prevent postoperative nausea and vomiting during scoliosis surgery

1 day
1 visit (in-person, surgery day)

Post-operative Monitoring

Participants are monitored for nausea, vomiting, and other adverse events post-surgery

Up to 10 days
Daily assessments (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Aprepitant
Trial Overview The study tests if Aprepitant can prevent nausea and vomiting after scoliosis surgery, compared with a placebo. Children will be randomly given either the drug or an inactive substance to see which works better.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AprepitantExperimental Treatment1 Intervention
Two doses of 40mg (2ml) Aprepitant
Group II: DextrosePlacebo Group1 Intervention
Two doses of dextrose (2ml)

Find a Clinic Near You

Who Is Running the Clinical Trial?

IWK Health Centre

Lead Sponsor

Trials
131
Recruited
112,000+

Findings from Research

Aprepitant, an antiemetic that blocks NK-1 receptors, was safely administered to 31 pediatric patients with a history or risk of postoperative nausea and vomiting (PONV), with no adverse effects reported.
In this cohort, PONV occurred in only 4 out of 31 patients, suggesting that aprepitant may be effective in reducing PONV, but further studies with larger sample sizes and comparisons to other treatments are needed to confirm its efficacy.
Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children's Hospital: A 12-Month Survey.Kanaparthi, A., Kukura, S., Slenkovich, N., et al.[2022]
The aprepitant triple regimen significantly improves the prevention of chemotherapy-induced nausea and vomiting (CINV) compared to the standard regimen, showing better complete response rates in overall, acute, and delayed phases across 51 randomized controlled trials.
While aprepitant reduces the risk of constipation, it is associated with a higher incidence of hiccups, indicating a generally favorable safety profile with some manageable side effects.
Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis.Qiu, T., Men, P., Xu, X., et al.[2022]
A population pharmacokinetic model for aprepitant was developed using data from 147 pediatric patients, showing that a weight-based dosing regimen for children under 12 and a fixed adult dose for adolescents effectively matches drug exposure levels seen in adults.
The study confirmed that aprepitant is effective for preventing chemotherapy-induced and postoperative nausea and vomiting in children and adolescents, supporting tailored dosing strategies for this age group.
Modeling and Simulation Analysis of Aprepitant Pharmacokinetics in Pediatric Patients With Postoperative or Chemotherapy-Induced Nausea and Vomiting.Chain, A., Wrishko, R., Vasilinin, G., et al.[2020]

References

Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. [2022]
Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects. [2019]
Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. [2022]
Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children's Hospital: A 12-Month Survey. [2022]
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis. [2023]
Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis. [2022]
Modeling and Simulation Analysis of Aprepitant Pharmacokinetics in Pediatric Patients With Postoperative or Chemotherapy-Induced Nausea and Vomiting. [2020]
Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security